FDA approves Eli Lilly's early Alzheimer's drug

The approval makes it the second drug on the U.S. market aimed at slowing progression of the debilitating neurological disease.

July 2, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | FDA approves Eli Lilly's early Alzheimer's treatment The treatment, donanemab, which will be sold under the brand name Kisunla, was shown to modestly slow the cognitive decline associated with the disease. By Elaine Chen and Matthew Herper CDC looks to expand capacity to test for H5N1 bird flu in people The CDC seems to be trying to avoid mistakes made early in the Covid-19 pandemic, when testing failures allowed undetected spread. By Megan Molteni Moderna receives $176 million from BARDA for mRNA influenza vaccines The Cambridge, Mass. company said Tuesday it will receive $176 million from HHS' BARDA to accelerate development of mRNA-based pandemic influenza vaccines. By Helen Branswell Adobe This AI chatbot was trained on drag queens, and it wants to help protect your sexual health AIDS Healthcare Foundation is rolling out an AI chatbot with a drag queen persona to make testing and treatment less scary. By Mohana Ravindranath STAT+ | The biotech scorecard for the third quarter: 19 stock-moving events to watch Events to watch will include data on a Novo Nordisk obesity drug and an FDA advisory panel hearing on AstraZeneca's checkpoint inhibitor Imfinzi. By Adam Feuerstein Opinion: Senate, FTC cracking down on pharma patent shenanigans In this First Opinion essay, FTC Chair Lina Khan and U.S. Sen. Dick Durbin urge action on drug company patent abuse as a way to lower high drug costs. By Dick Durbin and Lina M. Khan Anna Moneymaker-Pool/Getty Images STAT+ | How controversial was the decision by FDA's Peter Marks to approve Sarepta's gene therapy? Check its footnotes Marks' unilateral decision to overrule three different review teams and approve the Duchenne therapy looks even more surprising on a close examination. By Matthew Herper Q&A: The U.S. is losing control of hypertension. China's 'village doctors' have lessons Dan Jones, former president of the American Heart Association, says a new study of China's "village doctors" has relevance for Americans. By Elizabeth Cooney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser